Vendor, Warren, NJ
Cipla USA Inc.
UEI Q2MKMCP1CDT7, CAGE 7WV84
2 awards and $0 obligated between February 2, 2024 and July 15, 2026, 100% under full and open competition, against 500.5 offers on average where reported.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 36E79721D0016February 2, 2024, Full and Open Competition, 2 offers | Nac PharmaceuticalsDepartment of Veterans Affairs | Exercise Option Year 3, Effective April 1, 2024 to March 31, 2025 for Ambrisentan Tablets with Cipla Usa, INC.NAICS 325412, PSC 6505 | $0 |
| 36F79721D0092July 23, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | Voluntary TPRNAICS 325412, PSC 6505 | $0 |
- Product and service codes
- 6505 Drugs and Biologicals
- Transactions
- 19 across 2 awards